Literature DB >> 11337365

Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis.

J Lüttges1, H Galehdari, V Bröcker, I Schwarte-Waldhoff, D Henne-Bruns, G Klöppel, W Schmiegel, S A Hahn.   

Abstract

The presumed precursor lesions of pancreatic ductal adenocarcinoma were recently classified according to their increasing grade of dysplasia and were designated as pancreatic intraepithelial neoplasia (PanIN) 1 through 3. In this study, we tested whether molecular genetic alterations can be correlated with this classification and may help to further categorize the various PanIN grades. We determined the frequencies of allelic loss at chromosomal arms 9p, 17p, and 18q in 81 microdissected duct lesions of various PanIN grades, using a combination of whole genome amplification and microsatellite analysis. In addition we examined the p53 and Dpc4 protein expression patterns by immunohistochemical analysis. In PanIN-1, we did not detect allelic losses. In PanIN-2, allelic losses were found in increasing frequency, and were particularly high in those lesions with moderate-grade dysplasia (low grade, 20, 33, and 17%, loss at 9p, 17p, and 18q, respectively; moderate grade, 46, 77, and 58%). PanIN-3 and invasive carcinomas exhibited abundant losses. Abnormal p53 and Dpc4 protein expression was only rarely identified in PanIN-2 lesions, but occurred frequently in PanIN-3 lesions and invasive carcinomas. The combined genetic and protein expression data support a model in which allelic loss is the first hit in the biallelic inactivation of the p53 and DPC4 tumor suppressor genes. In addition, our data indicate that allelic loss analysis may be useful in separating PanIN-2 lesions with low-grade dysplasia from those PanIN-2 lesions with moderate-grade dysplasia, each potentially representing a distinct progression step toward invasive carcinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337365      PMCID: PMC1891939          DOI: 10.1016/S0002-9440(10)64123-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  23 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

2.  Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.

Authors:  E Heinmöller; W Dietmaier; H Zirngibl; P Heinmöller; W Scaringe; K W Jauch; F Hofstädter; J Rüschoff
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

3.  Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.

Authors:  R H Hruban; N V Adsay; J Albores-Saavedra; C Compton; E S Garrett; S N Goodman; S E Kern; D S Klimstra; G Klöppel; D S Longnecker; J Lüttges; G J Offerhaus
Journal:  Am J Surg Pathol       Date:  2001-05       Impact factor: 6.394

4.  Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53.

Authors:  J Lüttges; A Diederichs; M A Menke; I Vogel; B Kremer; G Klöppel
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

5.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.

Authors:  R E Wilentz; C A Iacobuzio-Donahue; P Argani; D M McCarthy; J L Parsons; C J Yeo; S E Kern; R H Hruban
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

6.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Authors:  M S Redston; C Caldas; A B Seymour; R H Hruban; L da Costa; C J Yeo; S E Kern
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

7.  Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis.

Authors:  G Klöppel; G Bommer; K Rückert; G Seifert
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1980

8.  Relation of pancreatic duct hyperplasia to carcinoma.

Authors:  S Kozuka; R Sassa; T Taki; K Masamoto; S Nagasawa; S Saga; K Hasegawa; M Takeuchi
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

9.  Morphological lesions associated with human primary invasive nonendocrine pancreas cancer.

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

10.  p53 and K-RAS alterations in pancreatic epithelial cell lesions.

Authors:  H Kalthoff; W Schmiegel; C Roeder; D Kasche; A Schmidt; G Lauer; H G Thiele; G Honold; K Pantel; G Riethmüller
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

View more
  59 in total

1.  Loss of heterozygosity or intragenic mutation, which comes first?

Authors:  R E Wilentz; P Argani; R H Hruban
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

2.  Bronchiolar columnar cell dysplasia--genetic analysis of a novel preneoplastic lesion of peripheral lung.

Authors:  Reinhard Ullmann; Massimo Bongiovanni; Iris Halbwedl; Susanna Petzmann; Margit Gogg-Kammerer; Anna Sapino; Mauro Papotti; Gianni Bussolati; Helmut H Popper
Journal:  Virchows Arch       Date:  2003-04-09       Impact factor: 4.064

Review 3.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

4.  Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer.

Authors:  Seung-Mo Hong; Audrey Vincent; Mitsuro Kanda; Julie Leclerc; Noriyuki Omura; Michael Borges; Alison P Klein; Marcia Irene Canto; Ralph H Hruban; Michael Goggins
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

5.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

6.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

7.  Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.

Authors:  N Tjarda van Heek; Alan K Meeker; Scott E Kern; Charles J Yeo; Keith D Lillemoe; John L Cameron; G Johan A Offerhaus; Jessica L Hicks; Robb E Wilentz; Michael G Goggins; Angelo M De Marzo; Ralph H Hruban; Anirban Maitra
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

8.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

9.  CpG island methylation profile of pancreatic intraepithelial neoplasia.

Authors:  Norihiro Sato; Noriyoshi Fukushima; Ralph H Hruban; Michael Goggins
Journal:  Mod Pathol       Date:  2007-12-21       Impact factor: 7.842

10.  Infrequent alteration of the DPC4 tumor suppressor gene in renal cell carcinoma.

Authors:  Marijana Popović Hadzija; Reno Hrasćan; Maja Herak Bosnar; Zarko Zeljko; Mirko Hadzija; Josip Cadez; Kresimir Pavelić; Sanja Kapitanović
Journal:  Urol Res       Date:  2004-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.